key: cord-0718403-i8mjonvt
authors: Rocco, Joseph M; Mallarino-Haeger, Christina; Randolph, Attiya H; Ray, Susan M; Schechter, Marcos C; Zerbe, Christa S; Holland, Steven M; Sereti, Irini
title: Hyperinflammatory syndromes after SARS-CoV-2 mRNA vaccination in individuals with underlying immune dysregulation
date: 2021-12-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1024
sha: 6a3029c2ad16fb185d995b0db04576e37f5e58f5
doc_id: 718403
cord_uid: i8mjonvt

The development of effective SARS-CoV-2 mRNA vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5-patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential.

The rapid generation of safe and effective mRNA vaccines has been an unprecedented success of the SARS-CoV-2 pandemic. Adverse events are extremely uncommon even in large population-database analyses [1] . However, exacerbations of underlying hematologic and autoimmune diseases have been reported post-vaccination [2] . Rare cases of possible vaccine-related hemophagocytic lymphohistiocytosis (HLH) have also been published after other SARS-CoV-2 vaccines [3, 4] . Given the widespread administration of these vaccines, it is essential to continue to monitor for rare adverse events and to identify patient populations at-risk. We describe five cases of hyperinflammatory reactions, including HLH, temporally associated to mRNA vaccination in people with underlying immune dysregulation.

A 52-year-old otherwise healthy man developed high fevers and abdominal pain the day after receiving the first dose of BNT162b2 mRNA-vaccine. He reported a viral syndrome four-months prior and malaise with low-grade fever the week before vaccination. Ten-days after vaccination, he was admitted with fevers, acute liver injury, and hypotension requiring vasopressors (additional clinical information in supplement). Labs demonstrated increased ferritin (8,130 ng/mL) and soluble CD25 (sCD25) ( Table-1) . Antibiotics were initiated, and infectious work-up noted only Epstein-Barr virus (EBV) viremia of 11.3-million IU/mL. Dexamethasone and etoposide were initiated for HLH, and his fever and hemodynamics initially improved. Bone marrow biopsy demonstrated hemophagocytosis and T-cell lymphoma. He was started on an etoposide-based chemotherapy regimen. His course was complicated by neutropenic fever, Bacteroides bacteremia, and refractory shock, from which he died.

A 53-year-old man developed interstitial lung disease (ILD) with biopsy proven non-specific interstitial pneumonia and positive anti-Ro/La and U1-RNP autoantibodies seven-months before presentation. Prednisone and mycophenolate were trialed without improvement and rituximab was planned, so he received BNT162b2 mRNA-vaccine. Four-days after vaccination, he developed fever and worsening hypoxia. Antibiotics were started, but his symptoms progressed requiring mechanical ventilation. Labs demonstrated new pancytopenia, hyperferritinemia (84,848 ng/mL), and increased sCD25. Bone marrow biopsy showed hemophagocytosis. Infectious evaluation revealed only EBV viremia (10,275 IU/mL). He was started on dexamethasone, anakinra, and intravenous immunoglobulin with improvement. His course was complicated by Pseudomonas bacteremia and autoimmune hemolytic anemia (AIHA), which responded to rituximab. Ventilatory support was weaned after three-months, and he was discharged to a rehabilitation facility.

A 57-year-old man with heart failure and well-controlled HIV developed malaise and nausea twelve-days after receiving the mRNA-1273 vaccine. Three-days later, he presented with hypothermia (30.2ºC) and hypotension. Labs revealed cytopenias with hemolysis, hyperferritinemia (>15,000 M a n u s c r i p t 4 ng/mL), and hypofibrinogenemia. Antibiotics and methylprednisolone were initiated. His hemodynamics and cytopenias stabilized over 72-hours. Sputum culture grew Mycobacterium avium complex (MAC) without consistent chest computed tomography (CT) and with negative mycobacterial blood cultures. He had Kaposi's-sarcoma herpesvirus (KSHV) viremia (3,063 IU/uL). His course was complicated by decompensated heart failure which improved with diuresis, and he was discharged. One-week later, he re-presented with encephalopathy and shock. Despite supportive care and antibiotics, he died two-days later. No autopsy was performed.

A 55-year-old woman presented with four-months of fevers, cytopenias, and hyperferritinemia. She had received steroids for presumed adult-onset Still's disease (AoSD) with transient improvement. Bone marrow culture grew MAC, and she also had pulmonary aspergillosis. Bone marrow biopsy revealed myelodysplastic syndrome (MDS) with excess blasts. She was diagnosed with GATA2 deficiency based on uniallelic GATA2 expression [5] . Her symptoms stabilized with antibiotics, but intermittent fevers persisted. In preparation for chemotherapy, she received the BNT162b2 mRNA-vaccine and developed high-grade fevers (40.1ºC) three-days after vaccination. Ferritin increased from 2,642 to 7,724 ng/mL, and she had worsening cytopenias. Due to pulmonary aspergillosis, steroids were avoided. Anakinra was trialed but not tolerated. Fevers continued but her labs stabilized over two-weeks, although she continued to need blood transfusions for anemia. She slowly recovered, and her infections improved with treatment.

A 48-year-old woman with HIV presented with disseminated MAC and immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART). Her course was complicated by HLH with multiorgan failure, which improved with steroids and antimycobacterials. Relapsing pulmonary IRIS flares developed on steroid weaning raising concern for underlying sarcoidosis. Infliximab was initiated and symptoms improved. After 1.5-years, when prednisone was weaned to 10mg, she received the mRNA-1273 vaccine. Four-days after vaccination she developed fevers with productive cough and pleuritic chest pain resembling her previous IRIS flares. Cultures were negative and CT showed worsening mediastinal lymphadenopathy. Infectious work-up was negative. In view of her prior severe IRIS, she was treated with high-dose prednisone and infliximab. She improved over 72-hours and steroids were rapidly weaned.

We describe five cases of hyperinflammation occurring after SARS-CoV-2 mRNAvaccination in people with preexisting immune dysregulation. All patients had negative SARS-CoV-2 PCR testing, and no clinical evidence of prior COVID-19. Symptoms began 1-12 days after vaccination, and everyone received immune suppression. Two of the five patients who developed HLH died within six weeks of presentation. In adults, HLH is a diverse hyperinflammatory syndrome characterized by immune-mediated pathology. Although typically classified as primary or secondary, its pathogenesis is complex and multifactorial [6] . Jordan and colleagues proposed categorizing HLH M a n u s c r i p t 5 by underlying immune predisposition into subgroups including malignancy, rheumatologic disease, immune-compromise, and treatment-associated [6] . Infection-associated HLH was not considered a separate entity as patients with any of these conditions may have an infectious trigger [7, 8] .

Our case series highlights the utility of this system, as each individual had a unique underlying immunologic disease. Due to the temporal association, it is possible the mRNA vaccination served as a trigger for the subsequent hyperinflammatory state. The pathophysiology of HLH is driven by enhanced T-cell activation and IFNγ production leading to severe macrophage activation, hypercytokinemia, and life-threatening inflammation [6, 7] . Messenger RNA vaccines have been shown to drive an acute expansion of activated CD4+ T-cells after the first injection [9] . Due to the importance of T-cells in HLH pathophysiology, it is possible this expansion could lead to increased IFNγ production and bystander activation triggering pathologic inflammation in at-risk individuals.

It is important to emphasize these patients had significant preexisting immune dysregulation, which was an independent predisposition to hyperinflammation. Patient-1 had T-cell lymphoma which is known to increase susceptibility to HLH. EBV can drive this pathogenesis by infecting both B-cells and T-cells [10] . Autoimmune diseases such as AoSD can predispose to HLH (referred to as macrophage activation syndrome [MAS]) [7] . HLH/MAS has also occurred with other rheumatologic diseases associated with ILD including Sjogren's syndrome and dermatomyositis [11].

Patient-3 had well-controlled HIV and a sputum culture which grew MAC without clinical evidence of mycobacterial infection. He had a KSHV viremia which has been implicated in hyperinflammatory syndromes in people with HIV [12] , however, a definitive diagnosis was not established. Despite the suspicion of additional immunodeficiency, no other immune disorder was identified and the etiology of HLH in this patient remains unknown. Patient-4 and Patient-5 had histories of HLH-like inflammation associated with disseminated mycobacterial infections in the setting of GATA2 deficiency and AIDS, respectively. Interestingly, they developed less fulminant inflammatory symptoms, highlighting the spectrum of clinical severity that can occur with different etiologies of hyperinflammation.

All patients in this case series developed hyperinflammatory responses after the first injection of an mRNA-based vaccine, but causality cannot be ascertained. Over 200-million people have been vaccinated against SARS-CoV-2 in the United States and unrelated disease processes may be detected in the peri-vaccination period. Unfortunately, the baseline population-rate of HLH in adults is difficult to estimate due to clinical heterogeneity and the variability in preexisting immune disorders [13] . This is further complicated by the absence of widely accepted and validated diagnostic criteria in adults making large database analyses unreliable [13] . However, vaccines are potential triggers of HLH in infants with genetic predispositions [14] . While this is not a well-described phenomenon in adults, the mechanism of mRNA vaccines is novel and their impact on T-cell responses is not fully known. This is the first case series describing hyperinflammatory syndromes following SARS-CoV-2 mRNA vaccination in individuals with preexisting immune dysregulation. Review of the Vaccine Adverse Event Reporting System (VAERS) database identified an additional 36-reports from across the United States of hyperferritinemic inflammatory syndromes described as HLH, MAS, or newonset Still's disease occurring after mRNA vaccinations [15] . Due to the limitations of the database with variability in recognition and reporting, complete clinical data and outcomes could not be confirmed for each case. M a n u s c r i p t 6 These rare observations should not change current vaccine recommendation guidelines. The risk of hyperinflammation and death from COVID-19 far outweighs the extremely low risk of severe vaccine-related adverse events [1] . Acute SARS-CoV-2 can also cause an HLH-like syndrome, and although its incidence is debated, it has been reported in up to 5% of severe cases of COVID-19 [16] . Therefore, the odds of developing HLH from SARS-CoV-2 infection remains markedly greater than any potential small peri-vaccination risk. In those without COVID-19, vaccination should be explored among the possible provocations of hyperinflammatory responses, including HLH. Individuals with persistent, severe inflammatory symptoms after vaccination should be evaluated for underlying immune dysregulation. They should have close follow-up and immune suppression, if required, should always be directed at the underlying disease process. Further study of the genetic and immunologic mechanisms predisposing to HLH is needed to improve diagnosis and treatment of this increasingly recognized hyperinflammatory syndrome. M a n u s c r i p t 10 

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination

Hemophagocytic lymphohistiocytosis after COVID-19 vaccination

GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)

Macrophage activation syndrome in the era of biologic therapy

Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination

Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis

Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases

Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS)

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Advances in understanding the pathogenesis of HLH

Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS)

Haemophagocytic syndrome and COVID-19

M a n u s c r i p t 7 NOTES Ethics Approval:All patients evaluated at the NIH provided written informed consent and were enrolled in one of three clinical protocols (NCT00404560, NCT00018044, NCT02147405). These protocols were approved by the National Institutes of Health Institutional Review Board.

Funding was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

All authors declare no conflicts of interest.A c c e p t e d M a n u s c r i p t